| Today's News and Trends | There is not agreement among the top structural heart experts if CT is required for left atrial appendage occlusion (LAAO), but a Henry Ford Hospital study shows it can improve outcomes. There is not agreement among the top structural heart experts if CT is required for left atrial appendage occlusion (LAAO), but a Henry Ford Hospital study shows it can improve outcomes. | |
| A decade ago, when TAVR was first cleared by the FDA, surgeons had concern about losing business. But unexpectedly, TAVR has helped also gain heart surgery cases. A decade ago, when TAVR was first cleared by the FDA, surgeons had concern about losing business. But unexpectedly, TAVR has helped also gain heart surgery cases. | |
| Ron Blankstein, MD, Brigham and Women's Hospital, explains recent advances in coronary computed tomography angiography (CCTA) technology. Ron Blankstein, MD, Brigham and Women's Hospital, explains recent advances in coronary computed tomography angiography (CCTA) technology. | |
| With the elevation of cardiac CT to a 1A indication in the 2021 Chest Pain Guidelines, there has been a large amount of interest in starting coronary artery CT angiography (CCTA) programs. With the elevation of cardiac CT to a 1A indication in the 2021 Chest Pain Guidelines, there has been a large amount of interest in starting coronary artery CT angiography (CCTA) programs. | |
| View a variety of images from the 2022 Society of Cardiovascular Computed Tomography (SCCT) meeting in Las Vegas. View a variety of images from the 2022 Society of Cardiovascular Computed Tomography (SCCT) meeting in Las Vegas. | |
| Devi Nair, MD, director of cardiac electrophysiology at St. Bernard's Healthcare, Jonesboro, Arkansas, explains some of the recent advances in transcatheter left atrial appendage (LAA) occlusion technology at the 2022 Transcatheter Valve Therapeutics (TVT) Structural Heart Summit. Devi Nair, MD, director of cardiac electrophysiology at St. Bernard's Healthcare, Jonesboro, Arkansas, explains some of the recent advances in transcatheter left atrial appendage (LAA) occlusion technology at the 2022 Transcatheter Valve Therapeutics (TVT) Structural Heart Summit. | |
| Michael Mack, MD, a key pioneer in transcatheter aortic valve replacement (TAVR), explains the history of TAVR and where things are headed. Michael Mack, MD, a key pioneer in transcatheter aortic valve replacement (TAVR), explains the history of TAVR and where things are headed. | |
| It was clear at TVT that tricuspid valve therapies will likely move ahead of new mitral therapies coming to market. Azeem Latib, MD, explained why. It was clear at TVT that tricuspid valve therapies will likely move ahead of new mitral therapies coming to market. Azeem Latib, MD, explained why. | |
| |
|
| | |
|